Popular Articles

Sexual Crimes: Narrow Window For Detection Of Knock-Out Drugs
Drug-facilitated sexual crimes are increasing. The Bonn Institute for Forensic Medicine has recorded that the number of examinations on the use of intoxicants in sexual offences within their catchment area increased 10-fold between 1997 and 2006. In the current edition of Deutsches Arzteblatt International, Burkhard Madea and Frank Musshoff present the modes of action and the detection windows for the most frequent substances (Dtsch Arztebl Int 2009; 106 (20): 341-347).
generic viagra online
British Medical Association Concerned About NHS Preparedness For New Working Time Regulations
With just days to go before the implementation of the 48-hour working week for junior doctors, the BMA"s junior doctors" leader warns that not all of the NHS is prepared for the European Working Time Directive.
News of the day
Researchers Uncover Approach For Possibly Eradicating HIV Infection
Researchers from the newly-established VGTI Florida and the University of Montreal have uncovered a possible method for eradicating HIV infection in the human body. The researchers have also revealed new information which demonstrates how HIV persists in the body - even in patients receiving drug treatments - and how the virus continues to replicate itself in individuals undergoing treatment. The research findings were published in the online version of the journal Nature Medicine on June 21 and will be featured in an upcoming print edition of the journal.
Diagnostics

Micrus Endovascular Announces Positive DeltaPaq Microcoil Study Results

Micrus Endovascular Corporation (NASDAQ:MEND) announced that study results presented recently at the 10th Congress of the World Federation of Interventional and Therapeutic Neuroradiology (WFITN) demonstrated that the DeltaPaq™ microcoil"s proprietary design appears to improve the uniformity of coil distribution within a cerebral aneurysm and the degree of microcoil packing in the aneurysm dome and neck, which may reduce the risk of aneurysm recurrence. Bernard R. Bendok, M.D., Assistant Professor of Neurological Surgery and Radiology, Department of Neurological Surgery of Northwestern University Feinberg School of Medicine, and Matthew Gounis, Ph.D., Director of the New England Center for Stroke Research at the University of Massachusetts, served as principal investigators for the Micrus-sponsored in vitro study. "The objective of this study was to assess whether the type of coil used had an impact on packing density and coil distribution within an aneurysm," said Dr. Bendok. "Conventional thinking has been that higher packing density reduces coil compaction and therefore leads to fewer retreatments. This study suggests that the DeltaPaq microcoil may improve uniformity of coil distribution and demonstrated that DeltaPaq had a statistically significant greater packing density compared with traditional helical and complex coil designs. This is the first study to examine coil distribution in different sections of an aneurysm. Uniformity of distribution, which was found to be superior with DeltaPaq, is a possible predictor of treatment durability." Ron Benitez, M.D., of the Atlantic Neurosciences Institute, Overlook Hospital in Summit, NJ, commented, "In general, my personal experience is that with Cerecyte® coils I see better outcomes than I did when using bare platinum coils. My approach today is to frame with one or two Presidio Cerecyte® or MicruSphere® coils, followed almost exclusively by DeltaPaq Cerecyte coils. The DeltaPaq coil is more conformable than other filling coils and therefore able to better find open voids in the aneurysm, leading to a more complete packing or filling of the aneurysm. I believe that the combination of Cerecyte with DeltaPaq"s filling capabilities will undoubtedly lead to a further reduction in my recanalization and retreatment rates." "We are singularly focused on developing and commercializing innovative products for the neurointerventional market," said John Kilcoyne, Chairman and CEO of Micrus Endovascular. "Our DeltaPaq features a completely new coil technology we call "Delta Wind," which was designed to improve the interventionalist"s ability to more thoroughly fill aneurysms. The market has responded very positively to DeltaPaq, which represented 13% of our revenues in our most recently reported quarter. We are equally excited about our DeltaPlush™ extra-soft, stretch-resistant finishing coil, also based on our Delta Wind technology, which we plan to launch later this fiscal year." Micrus Endovascular Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):